MacroGenics 'Serves' Early Stage Antibody Deal: Potential $450M
In a potential $450 million deal, MacroGenics Inc., has signed up the privately held French pharmaceutical company Servier as partner for MGA271, a first-in-class antibody targeting B7-H3, an antigen that is expressed in a long and growing list of solid tumors.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.